Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

New class of kinase inhibitors poised to join the anticancer arsenal

Nature Reviews Drug Discovery volume 11, pages 819–820 (2012)Cite this article

Subjects

Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine them with other cancer therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Alisa Opar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opar, A. New class of kinase inhibitors poised to join the anticancer arsenal. Nat Rev Drug Discov 11, 819–820 (2012). https://doi.org/10.1038/nrd3880

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3880

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer